dpp 4 inhibitors vs glp 1 agonist DPP-4 and GLP-1RAs: cardiovascular safety and benefits Lesson: A Clinical Overview of
Description
doi: 10.3389/fmed.2026.1752341 Received 23 November 2025 Revised 04 April 2026 Accepted 10 April 2026 Published 29 April 2026 Volume 13 - 2026 Edited by Wei Liu, Huazhong University of Science and Technology, China Reviewed by Jheng-Yan Wu, Chi Mei Medical Center, Taiwan Jennifer Teske, University of Arizona, United States Updates Copyright 2026 Fang, Zhu, Rao and Liu
Dani "My kids have told me multiple times I'm the funnest mom ever lately, I have more energy
The GIP receptor activation adds a complementary mechanism, improving insulin sensitivity and potentially enhancing the metabolic effects beyond what GLP-1 alone achieves
All protocols, dosages, and treatment insights referenced herein are based on published literature
Some studies have reported positive results for these diseases, exploring the potential for healthcare professionals
Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al
